Subgroup
|
N
|
Rs (95% CI)
|
Test(s) of heterogeneity
|
Significance test(s) of Rs = 0
|
P
a
|
---|
I2 (%)
|
P
|
Z
|
P
| |
---|
Overall
|
17
|
0.40 (0.24–0.57)
|
96.5
|
0.000
|
4.87
|
0.000
| |
Three experiments excluded
|
14
|
0.36 (0.24–0.47)
|
83.6
|
0.000
|
5.99
|
0.000
| |
Geographic area
|
Europe
|
10
|
0.33 (0.11–0.55)
|
95.7
|
0.000
|
2.98
|
0.003
|
< 0.001
|
Oceania
|
2
|
0.40 (0.03–0.76)
|
89.0
|
0.003
|
2.11
|
0.035
| |
South America
|
1
|
0.46 (0.17–0.75)
|
–b
|
–
|
3.14
|
0.002
| |
Africa
|
2
|
0.65 (0.05–1.25)
|
97.1
|
0.000
|
2.12
|
0.034
| |
North America
|
2
|
0.49 (0.30–0.69)
|
57.8
|
0.124
|
4.95
|
0.000
| |
Preparation method
|
No preparation
|
1
|
0.39 (0.20–0.58)
|
–
|
–
|
4.12
|
0.000
|
< 0.001
|
One preparation
|
15
|
0.41 (0.24–0.58)
|
96.7
|
0.000
|
4.63
|
0.000
| |
Swim up
|
6
|
0.65 (0.49–0.81)
|
93.0
|
0.000
|
8.07
|
0.000
|
< 0.001
|
Swim up/discontinuous gradient
|
2
|
0.61 (0.42–0.81)
|
50.9
|
0.153
|
6.07
|
0.000
| |
Discontinuous gradient
|
7
|
0.17 (0.10–0.25)
|
19.0
|
0.285
|
4.42
|
0.000
| |
Double preparation
|
1
|
0.33 (0.13–0.53)
|
–
|
–
|
3.28
|
0.001
| |
AR trigger
| | | | | | | |
Physiological trigger
|
8
|
0.49 (0.28–0.70)
|
96.8
|
0.000
|
4.51
|
0.000
|
< 0.001
|
HFF
|
3
|
0.46 (−0.03–0.95)
|
97.3
|
0.000
|
1.85
|
0.065
|
< 0.001
|
P
|
2
|
0.31(−0.01–0.63)
|
82.4
|
0.017
|
1.89
|
0.059
| |
ZP
|
3
|
0.63 (0.25–1.01)
|
96.0
|
0.000
|
3.22
|
0.001
| |
Nonphysiological trigger
|
9
|
0.33 (0.15–0.50)
|
89.0
|
0.000
|
3.68
|
0.000
| |
A23187
|
5
|
0.36 (0.13–0.58)
|
89.1
|
0.000
|
3.12
|
0.002
|
< 0.001
|
CAMP
|
1
|
0.12(−0.06–0.29)
|
–
|
–
|
1.26
|
0.206
| |
TPA
|
1
|
0.03 (−0.15–0.21)
|
–
|
–
|
0.29
|
0.773
| |
BSA-GlcNAc/A23187
|
1
|
0.46 (0.17–0.75)
|
–
|
–
|
3.14
|
0.002
| |
Mannose
|
1
|
0.59 (0.42–0.76)
|
–
|
–
|
6.68
|
0.000
| |
AR assay method
| | | | | | | |
Fluorescent labels
|
16
|
0.41 (0.25–0.58)
|
96.5
|
0.000
|
4.89
|
0.000
|
< 0.001
|
Direct immunofluorescence
|
15
|
0.40 (0.21–0.58)
|
96.7
|
0.000
|
4.22
|
0.000
|
0.224
|
With lection
|
10
|
0.53 (0.36–0.70)
|
94.9
|
0.000
|
6.08
|
0.000
|
< 0.001
|
FITC-PSA
|
7
|
0.55 (0.36–0.75)
|
95.7
|
0.000
|
5.57
|
0.000
|
< 0.001
|
FITC-PNA
|
2
|
0.40 (0.23–0.58)
|
18.3
|
0.269
|
4.51
|
0.000
| |
RITC-PSA
|
1
|
0.59 (0.42–0.76)
|
–
|
–
|
6.68
|
0.000
| |
With antibody
|
FITC-GB24
|
5
|
0.15 (0.05–0.25)
|
40.3
|
0.152
|
2.93
|
0.003
| |
Indirect immunofluorescence
|
Anti-CD46 antibody
|
1
|
0.68 (0.59–0.77)
|
–
|
–
|
14.14
|
0.000
| |
Triple stain
|
1
|
0.24 (0.03–0.45)
|
–
|
–
|
2.24
|
0.025
| |
- Rs spearman correlation coefficient, AR acrosome reaction, CI confidence interval, HFF human follicle fluid, P progesterone, ZP zona pellucida, CAMP cyclic adenosine 3′-5′-phosphate analogue, TPA phorbol ester, BSA-GlcNAc Neoglycoproteins with N-acetylglucosamine residues, FITC-PSA fluorescein isothiocyanate-conjugated Pisurn sativum agglutimm, FITC-PNA fluorescein isothiocyanate-conjugated peanut agglutinin, RITC-PSA rhodamine-conjugated Pisurn sativum agglutimm
- aComparison between subgroups with the Q test for heterogeneity
- bNot calculated